Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

ABSTRACT: This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.

DISEASE(S): Raltitrexed,Regorafenib,Third-line Treatment,Colorectal Neoplasms

PROVIDER: 2736418 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR